Key Highlights
- Product Revenue was USD 233,235, down from USD 437,602.
- Net loss was USD 2.6 million, or USD 0.75 per share.
- Research and development expense was USD 782,595.
- Cash stood at USD 306,191 at September 30, 2026.
Funding is the central question at 60 Degrees Pharmaceuticals (NASDAQ:SXTP). By its own estimate, cash and product revenues fund operations only until early December 2026. Beyond that point more Capital is needed immediately, and the company discloses substantial doubt about continuing as a going concern. Cash and cash equivalents were USD 306,191, against USD 1,510,065 at year-end 2025, and net cash used in Operating Activities for nine months was USD 6,419,897 versus USD 5,156,566.
Financing included net proceeds of about USD 3.4 million from the 2025 at-the-market agreement and about USD 0.7 million from a July 2026 private placement. The company says that agreement has no capacity left, owing to public-float limits in Form S-3. A Warrant inducement on November 9, 2026 brought in USD 471,329 at closing, net of Placement agent fees and before USD 75,000 of legal costs.
Quarterly Revenue and Losses
Third-quarter 2026 product revenue, net of discounts and rebates, was USD 233,235 versus USD 437,602. Cost of revenues was USD 330,766 versus USD 537,690, leaving a gross loss of USD 97,531 against USD 100,088. The prior-year quarter also included USD 90,960 of research revenues, and there were none in 2026.
Total operating expenses were USD 2,430,279 versus USD 2,316,647, and the loss from operations was USD 2,527,810 versus USD 2,325,775. Net loss including noncontrolling interest was USD 2,557,518 versus USD 2,317,036. After Series A cumulative dividends of USD 124,208, net loss attributed to common stockholders was USD 2,681,383. Loss per share was USD 0.75 versus USD 2.66, on weighted average shares of 3,553,432 versus 918,852, adjusted for the January 2026 reverse stock split.
Research and development expense was USD 782,595 versus USD 786,465, mainly contracted services and preparation for the babesiosis trial. General and administrative expense was USD 1,647,684 versus USD 1,530,182.
Nine Months and the Balance Sheet
Over nine months, the net loss was USD 6,913,259 versus USD 5,929,267, and product revenue was USD 603,225 versus USD 702,086. General and administrative expense was USD 5,266,805 versus USD 4,885,553, and Research and Development expense was USD 1,662,712 versus USD 1,389,191.
Total Assets were USD 3,094,102 versus USD 5,366,211, and total current assets were USD 2,564,256 versus USD 4,895,485. Inventory was USD 578,524, property and equipment, net, was USD 225,815 and intangible assets were USD 304,031. Total liabilities were USD 2,338,191, including Accounts Payable and accrued expenses of USD 1,773,519. Series A preferred stock of 68,080 shares was carried at USD 8,516,622. Total shareholders' Equity was USD 755,911 versus USD 3,379,416, and the accumulated Deficit was USD 54,804,030. The company had 4,484,622 shares outstanding as of November 16, 2026.
Products and Points to Follow
As a specialty pharmaceutical business, the company sells ARAKODA (tafenoquine), which won FDA approval in 2018 for malaria prevention, and works on medicines for infectious diseases. The pipeline holds new products built on the ARAKODA tafenoquine regimen, plus celgosivir and botanical extracts from Australian chestnut trees. Financing arrangements, the timing of vendor payments, the babesiosis trial and ARAKODA sales are the points to follow.






Please wait processing your request...